Fuelled by a visionary leadership team and a diverse, high-caliber Board, PharmaNest is rapidly expanding its circle of passionate scientific and clinical advisors who are accelerating breakthroughs in fibrosis research.

Executive Team

MATHIEU — **Mathieu Petitjean, Ph.D.**
**CEO**

**Li Chen, Ph.D.**
**Principal Investigator**

**Philippe Nore, MBA**
**Chief Business Officer**

**MD, To be Announced - Q4 2025**
**CMO**

Board of Directors

**Mathieu Petitjean, Ph.D.**
**Chairman and CEO**

**Pierre Claverie, Ph.D**
**Scalability and Resilience**

**Philippe Nore, MBA**
**Growth and Price**

**Henry Chang**
**Patient and Customer Advocate**

Clinical Advisory Board

**Pr. Vlad Ratziu, MD**
**Hepatologist**
**Hospital Pitié Salpêtrière, Paris**

**Pr. Arun J. Sanyal, MD**
**Hepatologist**
**Virginia Commonwealth University**

**Pr. Aras Mattis, MD, PhD**
**Gastrointestinal, Hepatobiliary Pathologist**
**U.C. San Francisco**

**Dr. Cynthia Behling, MD**
**Gastrointestinal, Hepatobiliary Pathologist**
**U.C. San Diego, Sharp Memorial Hospital**

**Pr. Mojgan Hosseini, MD**
**Gastrointestinal,Hepatobiliary Pathologist**
**U.C. San Diego**

News and Updates

Check our news archive here

November 7- 11, 2025: PharmaNest to present ten conference abstracts at the 2025 Liver Meeting - American Association for the Study of Liver Diseases Conference in Washington, D.C. in collaboration with major academic center and pharmaceutical companies developing a cure for MASH, Alcoholic Liver Disease and Cirrhosis.

September 11, 2025: PharmaNest, NIH and VCU Launch Confirmatory Retrospective Outcome Study With 1,765 Patients to Advance AI-Driven Digital Pathology in MASLD, Press release here

May 7-10, 2025: PharmaNest to present five digital Pathology and abstracts at the 2025 EASL Congress in Amsterdam, EU in collaboration with major Academic center and pharmaceutical companies developing a cure for MASH, Alcoholic Liver Disease and Cirrhosis. Press Release Here.

May 3-6, 2025: PharmaNest attends the 2025 Digestive Disease Week (DDW) in San Diego, USA to develop strategic relationships with pharmaceutical companies exploring anti-fibrotic claims in Crohn’s Disease.

May 1, 2025: PharmaNest Launches FibroMAP, the First Single-Fiber Phenotypic Tool for the Study of Fibrosis Across Biological Models and Indications. Press Release Here.

January 12-14, 2025: PharmaNest attends the 2025 JP Morgan Healthcare Conference to develop strategic relationships in the Drug Development and Investors communities.

January, 11 2025: PharmaNest to present at the 2025 MASH-Tag Conference (Deer Park, UT, USA): Along side with Dr. Andy Beck (PathAI), Dr. Dean Tai (Histoindex), Prs. Mary Rinella, Vlad Ratziu and Naim Alkhouri, Dr. Mathieu Petitjean presents PharmaNest’s contributions to “Recent Progress in Measuring Antifibrotic Effects: Data from MASH Clinical Trials” (Presentation here)

Offices:

100 Overlook Center, FL2, Princeton, NJ 08540

FibroNest Operations:

We deliver FibroNest worldwide via the Cloud.